Dr. Bo CHEN, has been a Director since April 23, 2018 and was re-designated as an executive Director on April 3, 2021 and currently serves as the chairman of our Board and our chief executive officer. Dr. Chen has been serving as the chief executive officer of Chengdu Keymed since December 2016 and its chairman since December 2018. Dr. Chen is primarily responsible for the overall strategic planning, business direction and operational
management of our Group.
Dr. Chen has extensive experience in the pharmaceutical industry. Dr. Chen founded Wuhan Huaxin Kangyuan Biopharma Co., Ltd. in June 2011, a biopharmaceutical company focusing on development of monoclonal antibodies drugs. Subsequently, from January 2013 to March 2015, Dr. Chen served as the general manager and an executive director at Shanghai Junshi Biosciences Co., Ltd., (“Junshi Bioscience”), a dual listed company in Hong Kong (stock code: 1877) and Shanghai (stock code: 688180) and subsequently served as the chief scientist until December 2016, Dr. Chen remained as a director of Junshi Bioscience until March 2018.
Dr. Chen obtained his bachelor’s degree in cell biology from Wuhan University in the PRC in July 1996. Dr. Chen proceeded to obtain his PhD. in fertility and molecular biology from the Albert Einstein College of Medicine of Yeshiva University in United States in September 2003.
Dr. Changyu WANG, has been a Director since March 3, 2021 and was re-designated as an executive Director on April 3, 2021. He is primarily responsible for directing and overseeing overall research and development management. Dr. Wang is the senior vice president of the Company and Chengdu Keymed.
Dr. Wang possesses more than 23 years of experience in research and development of biopharmaceuticals. From April 1998 to March 2001, he was a research scientist at Chiron Corporation. From April 2001 to August 2009, he was a senior scientist at Medarex, Inc., which was formerly listed on NASDAQ until acquisition by Bristol Myers Squibb, a company listed on the New York Stock Exchange (stock code: BMY). From September 2009 to December
2013, he was a senior scientist at Bristol-Myers Squibb. From January 2014 to February 2016, he was a director in cancer immunology at Pfizer Inc., a company listed on the New York Stock Exchange (stock code: PFE). Dr. Wang led the development of the world first PD-1 immune checkpoint inhibitor, Nivolumab, which has been approved for commercialization in 2014.
Dr. Wang obtained his bachelo's degree in microbiology from Wuhan University in the PRC in July 1983. He obtained his master's degree in virology from the National Vaccine and Serum Institute in September 1988. He obtained his PhD. in microbiology and immunology from the University of Colorado Medical Center in the United States in August 1994.
Dr. Gang XU, has been a Director since June 21, 2018 and was re-designated as an executive Director on April 3, 2021. Dr. Xu is primarily responsible for directing and overseeing drug discovery and early stage research. Dr. Xu is also the senior vice president of the Company and Chengdu Keymed and the executive director of Chengdu Kangnuo Xing.
Dr. Xu possesses more than 15 years of experience in research and development of biopharmaceuticals. From October 2010 to November 2015, he was a senior scientist at the Roche R&D Center (China) Ltd. He was once the general manager of Suzhou Bojuhua Biomedical Technology Co., Ltd., where he was responsible for pre-clinical research and operations. Dr. Xu has published research papers on immune system recognition, antibody display and bispecific antibodies in internationally renowned academic journals such as Nature Immunology and the Proceedings of the National Academy of Sciences of the USA.
Dr. Xu obtained his bachelor’s degree in genetics from Wuhan University in the PRC in July 1995. He obtained his PhD. in immunology from the Peking Union Medical College in the PRC in July 2004. He was a post-doctorate fellow in immunology at the University of Maryland School of Medicine in the USA from January 2005 to October 2010.
Mr. Qi CHEN, aged 46, has been a Director since June 21, 2018, and was re-designated as a non-executive Director on April 3, 2021. He participates in decision-making in respect of major matters such as corporate and business strategies.
From April 2001 to November 2015, he was a senior software engineer at Motorola Solutions (China) Co., Ltd. Since June 2017, he was an AI architect at Multipoint Life (Chengdu) Technology Co., Ltd.
Mr. Chen obtained his bachelor's degree in electrical engineering from in PRC in July 1996.
Dr. Min Chuan WANG, has been a Director since March 3, 2021, and was re-designated as a non-executive Director on April 3, 2021. He participates in decision-making in respect of major matters such as corporate and business strategies.
From May 2010 to March 2016, Dr. Wang served at Hony Capital as vice president of its health care department. Since August 2016, he has been the founding managing partner of 3H Health Investment, where he participates in matters related to the establishment and management of the healthcare investment funds and leads its biotech and biopharmaceutical investments.
Dr. Wang also sits on the Hong Kong Stock Exchange's Biotech Advisory Panel and the HKSAR Innovation and Technology Fund's Research Project Assessment Panel.
Dr. Wang received his bachelor's degree in pharmacy from Peking University in July, 2001. He then obtained his M.Phil. and his Ph.D. from Cambridge University in the United Kingdom in July 2009.
Mr. Yilun Liu, has been a Director since March 3, 2021, and was re-designated as a non-executive Director on April 3, 2021. He participates in decision-making in respect of major matters such as corporate and business strategies.
Mr. Liu has experience working in the financial industry, including serving as the head of special situation at Anatole Investment Management Limited. Since April 2018, Mr. Liu has been an executive director at Boyu Capital.
Mr. Liu received his bachelor of science degree in marketing from Fudan University in the PRC in July 2009. He then obtained his master of business administration degree from Columbia Business School in May 2015.
Prof. Xiao-Fan WANG, was appointed as an independent nonexecutive Director on April 3, 2021. He is responsible for providing independent advice and judgment to our Board.
Prof. Wang is currently Donald and Elizabeth Cooke Professor of Experimental Oncology and Professor of Pharmacology and Cancer Biology at Duke University Medical Center. In November 2017, He was elected as a foreign academician of the Chinese Academy of Sciences. Since 2012 to 2013, he served as the president of the Society of Chinese Bioscientist in America. Since 2010, he has served as a member of the Expert Group of the Major Science Program of the PRC Ministry of Science and Technology. He was a member of the Overseas Expert Advisory Committee of the Overseas Chinese Affairs Office of the State Council.
Prof. Wang has published more than 160 papers and have been cited more than 16,000 times. From 1992 to 1998, he was an assistant professor in the Department of Pharmacology and Cancer Biology of Duke University. He became an associate professor in 1998, and was promoted to full professorship in 2003. He was appointed the Donald and Elizabeth Cooke Distinguished Professor in 2009.
Prof. Wang obtained his bachelor of science degree in biochemistry from Wuhan University in the PRC in 1982. In 1986, he received his Ph.D. from the University of California, Los Angeles, and then worked as a postdoctoral researcher at the Massachusetts Institute of Technology.
Prof. Yang KE, was appointed as an independent non-executive Director on April 3, 2021. She is responsible for providing independent advice and judgment to our Board.
Prof. Ke is currently the director of Laboratory of Genetics of Peking University Cancer Hospital and an international member of the United States National Academy of Medicine. Prof. Ke is also Vice-president of the Peking University Alumni Association, President of the Peking University Health Science Center Alumni Association, Vice-president of the Chinese Medical Association, President of the Health Professional Education Committee of the Chinese Association of Higher Education, and Vicechairperson of the Steering Committee of Clinical Medicine of the Committee of Academic Degrees of the State Council.
Prof. Ke's research focus is on the upper gastrointestinal tumors, including the cloning of gastric cancer related genes and the functional study of such genes. Together with her team, she has also established the population cohort in esophageal cancer high incidence regions in China, studied the etiology of esophageal cancer, and evaluated the effects and economic efficacy of early screening of the disease. She has published more than 100 papers and had registered patents and been granted awards at national and provincial levels for technological and educational achievements.
Prof. Ke graduated from Beijing Medical College (subsequently known as Beijing Medical University and currently known as Peking University Health Science Center in 1982. From 1985 to 1988, Prof. Ke worked at the National Cancer Institute of the National Institutes of Health of the United States as a postdoctoral fellow.
Mr. Cheuk Kin Stephen LAW, was appointed as an independent non-executive Director on April 3, 2021. He is responsible for providing independent advice and judgment to our Board.
Mr. Law worked at Wheelock and Company Limited, a company formerly listed on the Stock Exchange (stock code: 0020) and The Wharf (Holdings) Limited, a company listed on the Stock Exchange (stock code: 0004) from 1995 to 2000; Morningside Group from 2000 to 2006; and TPG Growth Capital (Asia) Limited from July 2006 to September 2012, where he last served as a managing director. Mr. Law served as (the chief financial officer of Guoco Group Limited, a company listed on the Stock Exchange (stock code: 0053) from October 2012 to June 2013; (ii) the finance director of MTR Corporation Ltd., a company listed on the Stock Exchange (stock code: 0066) from July 2013 to July 2016; (iii) an adjunct professor of the Hong Kong Polytechnic University from 2015 to 2017; (iv) the independent non-executive director of AAG Energy Holdings Limited, a company listed on the Stock Exchange (stock code: 2686) from July 2016 to September 2018 and (v) an independent non-executive director of Stealth BioTherapeutics Inc., a company listed on NASDAQ (ticker symbol: MITO) from June 2018 to July 2019. He has been the managing director of ANS Capital Limited since 2017.
Mr. Law has been an independent non-executive director of the following companies which are listed on the Stock Exchange: (i) China Everbright Limited (stock code: 0165) since May 2018; (ii) Somerley Capital Holdings Limited (stock code: 8439) since February 2019; (iii) Bank of Guizhou Co., Ltd. (stock code: 6199) since November 2018, (iv) China Galaxy Securities Co., Ltd. (stock code: 06881) since June 2020 and (v) CSPC Pharmaceutical Group Limited (stock code: 1093) since March 2021. Mr.Law is also an independent non-executive director of Bio-Thera Solutions, Ltd. .
Mr. Law obtained his bachelor's degree majoring in science (civil engineering) from University of Birmingham in the United Kingdom in July 1984 and his MBA degree from University of Hull in the United Kingdom in July 1996. Mr. Law was a council member of the Hong Kong Institute of Certified Public Accountants (HKICPA) from January 2010 to December 2017. Mr. Law is now a member of the HKICPA and the Institute of Chartered Accountants in England and Wales, a council member of Hong Kong Business Accountants Association Ltd. (HKBAA) and an expert accounting consultant appointed by the Ministry of Finance in the PRC. Mr. Law is also a council member of The Hong Kong Independent Non-Executive Director Association Limited (HKiNEDA). Mr. Law has accounting qualifications in Hong Kong and the United Kingdom.
Prof. Linqing Liu, aged 46, is an independent non-executive Director of our Company and was appointed as an independent non-executive Director on April 3, 2021. Prof. Liu has taught at the Economics and Management School of Wuhan University since July 2002 and now serves as a professor and doctoral supervisor. He is also the director of the Department of Business Administration of Wuhan University and the director of the Institute of Business Strategic Management of Wuhan University. His research areas focus on corporate strategic management, business administration and management education. Prof. Liu was an independent non-executive director of Aotecar New Energy Technology Co., Ltd (formerly known as Jiangsu Kingfield Garments Co., Ltd. (stock code: 002239), a listed company on the Shenzhen Stock Exchange. Prof. Liu was an independent non-executive director of Wuhan Humanwell Hi-tech Ind. Co., Ltd. (stock code: 600079), a listed company on the Shanghai Stock Exchange from 2009 to 2015. He is currently an independent director of HuBei SanFeng Intelligent Convey Co., Ltd. (stock code: 300276) and Wuhan P&S Information Co., Ltd. (stock code: 300184), both listed on the Shenzhen Stock Exchange as well as Mabpharm Limited (stock code: 2181), a company listed on the Stock Exchange.
Prof. Liu graduated from Wuhan University, with a double bachelor degree in science and management and a master degree in management in 1995 and 1999, respectively. Prof. Liu obtained a doctorate degree in management from Wuhan University in 2002. Prof. Liu was accredited as a certified public accountant by the Hubei Institute of Certified Public Accountants in December 2009.
Dr. Bo CHEN (Chairperson)
Prof. Xiao-Fan WANG
Prof. Linqing LIU
Prof. Xiao-Fan WANG (Chairperson)
Dr. Changyu WANG
Prof. Yang KE
Mr. Cheuk Kin Stephen LAW (Chairperson)
Mr. Qi CHEN
Prof. Linqing LIU